<DOC>
	<DOCNO>NCT02608203</DOCNO>
	<brief_summary>Somatostatin receptor overexpressed GEP-NETs visualize vivo radiolabeled somatostatin-analogs . During last decade , conventional scintigraphy use 111In-DTPA-Octreotide ( often name somatostatin receptor scintigraphy SRS ) consider gold standard nuclear imaging technique evaluation GEP-NETs . However , SRS may suboptimal clinical set low intrinsic resolution technique selectivity SST2 . Its overall sensitivity estimate 60-70 % ( per lesion analysis ) , even use recent SPECT-CT camera . MRI also high sensitivity CT SRS detection liver metastases GEP-NETs . In recent year , positron emission tomography ( PET ) imaging , high resolution sensitive technology , gain increase role oncology . It also evaluate GEP-NETs somatostatin agonist ( SSTa ) radiolabelled Gallium-68 [ 68Ga ] , positron emitter promise result . Its diagnostic sensitivity clearly superior SRS many European center already replace SRS [ 68Ga ] -PET-SSTa . Currently , three different [ 68Ga ] -coupled peptide use trial : DOTA-TOC , DOTA-TATE DOTA-NOC excellent affinity SST2 ( IC50 : 2.5 ; 0.2 1.9 nM , respectively ) . Sensitivities DOTA-TOC DOTA-TATE PET/CT quite similar . [ 68Ga ] -DOTANOC also bind SST5 recently find detect significantly lesions SST2-specific radiotracer [ 68Ga ] -DOTATATE patient GEP-NETs require evaluation . It therefore important determine interest [ 68Ga ] -DOTANOC combine standard diagnosis strategy GEP-NETs evaluate medicoeconomic impact add [ 68Ga ] -DOTANOC work-up patient . The investigator hypothesis [ 68Ga ] -DOTANOC modify management least 20 % patient adapt way accord 2012 ENETS guideline comparison decision base standard imaging work ( multiphasic WB CT , liver MRI SRS ) . 110 patient include prospectively 5 different French experience center ( Marseille , Bordeaux , Toulouse , Paris , Clermond-Ferrand ) .</brief_summary>
	<brief_title>68 Ga-DOTANOC PET/CT GEP-NETs</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>1 . Age &gt; 18 year , affiliation Social Security . 2 . Written consent patient . 3 . Patients follow 5 situation : GEPs without metastasis . GEPs unilateral liver metastasis candidate unilateral hepatectomy . GEPs unknown primary tumor . GEPS livers metastasis candidate liver transplantation . Metastatic GEPs grade 1 2 tumour negative SRS . 4 . Reference image within last 3 month : multiphasic total body CT scan , liver MRI SRS ( SPECT/CT ) . 1. minor subject . 2 . Pregnant breastfeeding . 3 . Absence therapeutic alternative metastatic GEP . 4 . Undifferentiated GEP and/or metastatic GEPs grade 3 tumour .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>